PMBS Stock UPDATES Puramed Bioscience (PMBS) 0.0001 09/08/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 8, 2014 at 12:19 PM

Puramed Bioscience (PMBS) 0.0001 $PMBS

PuraMed BioScience Completes the First Production of MigraPure® Gel
PR Newswire - Wed Aug 13, 11:28AM CDT
PuraMed BioScience®, Inc., (OTCPink

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company has completed its first batch of its patented, sublingual MigraPure® gel containing feverfew and ginger with an enhanced flavor.

PuraMed BioScience to add Cannabis-based epilepsy medication to its product line
M2 - Wed Aug 06, 5:53AM CDT
OTC medicinal company PuraMed BioScience (Other OTC

MBS) said on Tuesday that it intends to begin testing a new hemp-based epilepsy medication in the fourth quarter of 2014.

PuraMed BioScience Develops a Cannabis-based Epilepsy Medication
PR Newswire - Tue Aug 05, 1:00PM CDT
PuraMed BioScience®, Inc., (OTCPink: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it plans to begin testing of a new hemp-based epilepsy medication in the fourth quarter of 2014.

PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M
PR Newswire - Wed Jul 30, 12:57PM CDT
PuraMed BioScience®, Inc., (OTCPink

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is rebranding the LipiGesic® M name along with the name's red and yellow logo. The former will be replaced with the trademarked name MigraPure® going forward. The new name, logo, and color palette of PuraMed's homeopathic, natural migraine pain reliever will be reintroduced into selected segments of the retail marketplace.

PuraMed BioScience forms corporate sponsor partnership with Operation Troop Aid for US military
M2 - Wed Jul 23, 7:38AM CDT
Healthcare company PuraMed BioScience (PNK

MBS) reported on Tuesday the launch of a corporate sponsor agreement with Operation Troop Aid in aid of the US military.

PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages
PR Newswire - Tue Jul 22, 7:49AM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is a corporate sponsor of Operation Troop Aid.

PuraMed BioScience Announces Product Donation at a Sponsorship Level to Operation Gratitude
PR Newswire - Tue Jul 08, 8:11AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is now a corporate sponsor of Operation Gratitude.

PuraMed BioScience Explores the Development of Hemp and THC-Free Cannabis Formulations to Expand Its Product Line
PRWeb - Mon Mar 24, 6:09AM CDT
PuraMed BioScience(R), Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that it is seriously exploring the development of cannabinoid and hemp-based formulations to expand its natural and homeopathic product line.

Energy Utilities Focus on Providing Reliable and Safe Service while Meeting Compliance Standards
PR Newswire - Wed Feb 26, 7:00AM CST
To streamline and standardize gas compliance processes and adapt to the demands of the energy service and delivery industry, Ameren Corporation has turned to the mobile workforce management market leader, ClickSoftware Technologies Ltd. (NasdaqGS: CKSW). The implementation of ClickSoftware's scheduling and mobility offering for gas compliance processes will eliminate paper inspection forms and improve data quality, improve flexibility to adapt to rapidly changing regulatory requirements, and provide management with greater visibility into compliance activities.

Merger Approval, Financial Results, Conference Call Schedule, and Stock Price Updates - Research Report on Omnicom, Global Payments, FleetCor, Interpublic, and Fiserv
PR Newswire - Wed Jan 15, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.

PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
PR Newswire - Thu Aug 29, 11:03AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that it will discuss LipiGesic M on Armed Forces Network.

PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
PR Newswire - Thu Aug 22, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it will sponsor the 5th Miles for Migraine Race San Francisco by supplying $5,000 of LipiGesic M for the participants.

PuraMed BioScience Inc signs LipiGesic M distributor agreement with OuterBanks Outdoors
M2 - Thu Aug 15, 10:13AM CDT
Healthcare company PuraMed BioScience Inc (OTC BB

MBS) reported on Wednesday the launch of an exclusive distribution agreement to sell LipiGesic M on Amazon.com..

PuraMed BioScience Announces Distributor Agreement with OuterBanks Outdoors
PR Newswire - Wed Aug 14, 1:08PM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it has entered into an exclusive distribution agreement with OuterBanks Outdoors to sell LipiGesic® M, its homeopathic formulation of feverfew and ginger for treatment of acute migraine, on Amazon.com.

LipiGesic M is the only recommended first-line therapy for acute migraine that has no evidence of rebound headache
PR Newswire - Mon Aug 05, 2:44PM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that its product, LipiGesic® M, a homeopathic formulation of feverfew and ginger that eliminates migraine pain and associated symptoms, is the only recommended first-line therapy for acute migraine in the retail market today that has shown no evidence of rebound or medication-overuse headache.

PuraMed BioScience Inc reports 42.6m outstanding shares in issue
M2 - Wed Jul 03, 4:36AM CDT
Medicinal products company PuraMed BioScience Inc (OTC BB

MBS) declared on Tuesday that its current common shares issued and outstanding totalled 42,610,297 as of 30 June 2013.

PuraMed BioScience Announces Common Shares Outstanding of 42.6 Million
PR Newswire - Tue Jul 02, 10:27AM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces update of current share structure.

PuraMed BioScience® Announces Science Behind LipiGesic® M Migraine Treatment
PR Newswire - Fri Jun 21, 10:05AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the science behind LipiGesic® M, its homeopathic, over-the-counter migraine medication.

PuraMed BioScience® Announces Interview on Big Biz Show Discussing LipiGesic® M
PR Newswire - Mon Jun 10, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an interview conducted on Big Biz Show with PuraMed BioScience's CEO Russ Mitchell to discuss and inform listeners about PuraMed BioScience's flagship product, LipiGesic® M.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sentra Snags $150M to Shield Data in AI Era

By Kelly Martin Updated Nov 4, 2026 Category News Views 237

Agents in the Data Game Who would've thought data would need protection from its own minders? That's what Sentra's addressing with their smart pivot to 'agentic' data security. AI agents are out there gobbling data faster than a trader overdosing on coffee during a bull run. As AI's pace accelerates, Sentra spotted an opportunity to safeguard data from unauthorized eyes....

Bascom's $30.8M Vegas Refi Amid Market Hurdles

Diving into the Vegas Real Estate Scene Alright, folks, let's roll up our sleeves and talk about something that's got my attention—Bascom Group's recent $30.8 million refinance of the Gateway Villas Apartments in Las Vegas. This ain't just another vanilla transaction in the back pages of some real estate journal. It's a play that screams strategy, especially in a world...

U.S. Lighting Game-Changer: Brandon, C.U. Phosco Align

This Ain't Just Another Merger Right off the bat, let's get one thing straight: this Brandon Industries and C.U. Phosco partnership isn't your run-of-the-mill handshake deal. Nope, this one's got some heft—like striking oil in your driveway. When you fuse over a century of lighting smarts across the Atlantic, expect the lights to shine a little differently over here....

Ophthalmic Equipment Market Set for Growth Surge by 2031

Eyeing the Road Ahead: Vital Market Growth Insights We've got ourselves a sector on the move. The ophthalmic equipment market, pegged at USD 21.2 billion in 2026, is set to climb up to a whopping USD 30.5 billion by 2031. Knowing that it’s growing at a steady clip of 7.5% CAGR over these years, there’s more than just a glimmer of opportunity for those savvy enough to...

Major Rally Lifts Dow Amid Key Stock Moves

Forget your usual day at the office, folks; Wednesday on Wall Street was anything but routine. The Dow Jones shot up a dazzling 1,572.58 points, reclaiming vital ground over an important technical threshold like the heavyweight it is. There's more cooking under the hood than mere index moves. We've got stocks jumping the charts like everyone's playing hopscotch, stirring...

Texans Credit Union Ranks High in Workplace Satisfaction

Building a Culture of Value and Growth Try saying no to recognition when you prioritize your people, and Texans Credit Union knows it well. Their consistent Top Workplace ranking—four years running, mind you—speaks volumes about a company truly valuing its workforce. Landing at No. 6 among midsize companies in The Dallas Morning News' 2026 D-FW list, they’re...

Stoneridge Navigates Challenges; Revises 2026 Outlook

Q3 Performance: Growth Mixed with Setbacks If you thought 2026 was going to be a breeze for Stoneridge Inc. (NYSE:SRI), think again. This quarter, the company reported some sales growth, but they're also battling a hefty arbitration loss that's thrown a wrench into their plans. Let’s dive into the numbers before I spill more beans on what this means for investors hoping...

Grant Davis Joins Assembly Health as CXO

By Olivia Taylor Updated Nov 4, 2026 Category News Views 101

Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...

Squalane in K-Beauty: Revolutionizing Skin Care Routines

The Spotlight's on Squalane in K-Beauty Korean beauty trends are usually at the pulse of global skincare, and if you’ve been watching, there’s a new kid making waves: squalane. Now, before you wrinkle your brow wondering why this old-timer's getting all the love, let me break it down. Squalane is adding a new sheen to K-beauty’s obsession with hydration and skin...

Verismo's SynKIR™-310 Shows Promise in Phase 1 Trials

KIR-CAR: A Fresh Take on Cancer Treatment So, Verismo Therapeutics is at it again with their KIR-CAR platform. They're set to present interim data at this year's ASH Annual Meeting. To all those following B-cell non-Hodgkin Lymphoma (B-NHL) treatments, pay attention. SynKIR™-310, a CD19-targeted therapy, is showing some real promise. The science behind this is like...